Marketing in drug development phase is quite different to “marketing” in the general sense of the word.
Very involved at all key stakeholder levels and a lot more strategic in planning, exactly what is needed here at RAC to map out the correct path.
“Global & US lead, working within our ultra rare disease product/portfolio eg. "Leniolisib". A matrix leadership position with the accountability to collaboratively lead the commercial & clinical teams to execute a successful go to market strategy & registration process across multiple affiliates”
Understand you want stone evidence in the form of an announcement because you can’t analyse the opportunity very well, usually buying when the risk has been removed means your paying multiple’s compared to what you could have, each to their own.
General Comments / Chat, page-8036
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |